Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk

NCT05297617 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

696

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Anti-aromatase inhibitor

Sponsor

UNICANCER

Collaborators

[object Object]